Pharma BD Deal Intelligence
A $40M upfront, $1.421B-milestone licensing deal giving Nuvectis ex-China rights to Haisco's NXP100 (Complement Factor B inhibitor, two MAAs under China review for paroxysmal nocturnal hemoglobinuria) and NXP200 (paradox-breaker BRAF inhibitor in Phase 1b for BRAF-mutated solid tumors)—a bet on China-originated assets reaching Western markets via royalty-bearing option structure.
Two-asset China-origin in-license broadening Nuvectis into complement and BRAF oncology
Full analysis, sources & comparables →Nuvectis Pharma in-licensed exclusive worldwide ex-China rights to two clinical-stage compounds from Haisco Pharmaceutical Group: NXP100, a once-daily oral Complement Factor B inhibitor with two MAAs under review in China for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oral paradox-breaker BRAF inhibitor in Phase 1b in China for BRAF-mutated solid tumors. Haisco receives up to $40M in upfront/near-term payments, up to $1.421B in milestones, plus tiered royalties.
In June 2026 Nuvectis Pharma in-licensed exclusive ex-China rights to two clinical-stage compounds from Haisco Pharmaceutical Group for $20M upfront plus milestones and royalties (total deal value up to ~$1.46B). NXP100 (HSK39297) is a once-daily oral Complement Factor B inhibitor in late-stage development for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN); NXP200 is a 'paradox-breaker' BRAF inhibitor in Phase 1b showing durable responses across BRAF-mutant tumors. Haisco retains India and certain Southeast Asia rights for NXP100; composition-of-matter patents run to 2043 (NXP100) and 2042 (NXP200).
Nuvectis in-licenses ex-China rights to Haisco's NXP100 (CFB inhibitor) and NXP200 (BRAF inhibitor) for $20M upfront + milestones/royalties (up to ~$1.46B total).
Modest $20M upfront for two clinical-stage assets with large biobucks; value is milestone-/royalty-weighted and depends on ex-China clinical replication and development execution by a small-cap licensee.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nuvectis Pharma, Inc. / Haisco Pharmaceutical Group Co., Ltd. (this deal) | 2026 | $1.5B | 59 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2026 deals · Hematology deals